Physician profile
Daniel D Cho
NPI 1346433828
$7,805.05
in general payments reported to CMS, 2019-2025
33 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $652 · 2021: $1,545 · 2022: $1,552 · 2023: $633 · 2024: $1,187 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,698 · Education: $67.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,698.12 |
| Education | $67.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,677.00 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $665.94 | 2019-2024 | |
| Janssen Biotech, INC. | $565.00 | 2020-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $511.81 | 2020-2024 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $466.27 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $394.04 | 2019-2024 | Dificid |
| Boston Scientific Corporation | $360.62 | 2019-2025 | Exalt Model D, Axios |
| Celgene Corporation | $273.31 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $247.06 | 2020-2025 | Entyvio |
| Ironwood Pharmaceuticals, INC | $240.78 | 2020-2025 | Linzess |
| Pfizer INC. | $171.99 | 2020-2025 | |
| Ardelyx, INC. | $142.92 | 2024-2025 | Ibsrela |
| Alfasigma USA, INC. | $117.36 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $103.16 | 2024-2025 | Iqirvo |
| Organon LLC | $96.54 | 2021-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $86.79 | 2023-2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $84.84 | 2020-2024 | |
| Genzyme Corporation | $81.62 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $73.47 | 2024 | Stelara |
| Nestle Healthcare Nutrition INC. | $72.67 | 2021-2022 | |
| Amgen INC. | $60.69 | 2021 | |
| Lilly USA, LLC | $53.16 | 2025 | Omvoh |
| Celltrion USA INC. | $47.15 | 2023-2024 | Zymfentra, Yuflyma |
| Redhill Biopharma INC. | $40.75 | 2021 | |
| Phathom Pharmaceuticals, INC. | $31.85 | 2025 | Voquezna |
| Ethicon US, LLC | $27.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.20 | 2025 | Eliquis |
| Braintree Laboratories, INC. | $23.23 | 2025 | Suflave |
| Novo Nordisk INC | $21.85 | 2025 | Wegovy |
| Qol Medical, LLC | $16.32 | 2021 | |
| W. L. Gore & Associates, INC. | $12.78 | 2020 | |
| Shionogi INC | $11.18 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.